Кенија - Енглески - Pharmacy and Poisons Board

doxorubicin hydrochloride. - concentrate for solution for infusion - 1 ml contains 2 mg doxorubicin hydrochloride - doxorubicin

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

sun pharma global fze - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - - cardiomyopathy: myocardial damage, including acute left ventricular failure can occur with doxorubicin. the risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks. the risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. assess lvef before and regularly during and after treatment with doxorubicin [see warnings and precautions (5.1)]. - secondary malignancies: secondary acute myelogenous leukemia (aml) and myelodysplastic syndrome (mds) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see warnings and precautions (5.2)]. extravasation and tissue necrosis: extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.immediately terminate the drug, and apply ice to the affected area [see warnings and precautions (5.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

zydus lifesciences limited - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - doxorubicin hcl is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma non-hodgkin lymphoma metastatic breast cancer metastatic wilms? tumor metastatic neuroblastomas metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - doxorubicin hcl is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma non-hodgkin lymphoma metastatic breast cancer metastatic wilms? tumor metastatic neuroblastomas metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - doxorubicin hcl is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma non-hodgkin lymphoma metastatic breast cancer metastatic wilms? tumor metastatic neuroblastomas metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - doxorubicin hcl is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma non-hodgkin lymphoma metastatic breast cancer metastatic wilms? tumor metastatic neuroblastomas metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - doxorubicin hydrochloride -

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - doxorubicin hydrochloride - concentrate for solution for infusion - 2 milligram(s)/millilitre - anthracyclines and related substances; doxorubicin